KHS101

09/15/2015 - "KHS101, a TACC3 inhibitor, may serve as a novel therapeutic agent for HCC patients with tumors characterized by high TACC3 expression. "
12/15/2022 - "Among them, the most potent compound 7g exhibited about 10-folds more potent antiproliferative activities than KHS101 in various cancer cell lines. "
01/01/2018 - "In two intracranial patient-derived xenograft tumor models in mice, systemic administration of KHS101 reduced tumor growth and increased survival without discernible side effects. "
01/01/2018 - "We showed that the synthetic small-molecule KHS101 promoted tumor cell death in diverse GBM cell models, independent of their tumor subtype, and without affecting the viability of noncancerous brain cell lines. "
01/01/2018 - "KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice."

01/01/2018 - "In this study, we show that a small molecule TACC3 inhibitor, KHS101, suppresses cell growth, motility, epithelial-mesenchymal transition (EMT), and breast cancer cell stemness while it induces apoptotic cell death. "
01/01/2018 - "Our findings therefore provide a new insight into the potential mechanisms of the action of KHS101 and suggest its possible use as a dual or multi-targeting mitotic inhibitor in breast cancer."

01/01/2018 - "KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice."
12/15/2022 - "Discovery of novel analogs of KHS101 as transforming acidic coiled coil containing protein 3 (TACC3) inhibitors for the treatment of glioblastoma."

11/01/2017 - "This implies that KHS101 has therapeutic potential for the treatment of opioid addiction."